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Abstract
Background: Microalbuminuria is an independent risk factor for cardiovascular and kidney disease and a predictor
of end organ damage, both in the general population and in persons with HIV (PWH). Microalbuminuria is also an
important risk factor for mortality in PWH treated with antiretroviral therapy (ART). In the ongoing Renal Risk Reduction (R3) study in Nigeria, we identified a high prevalence of microalbuminuria confirmed by two measurements
4–8 weeks apart in ART-experienced, virologically suppressed PWH. Although Stage 1 or 2 hypertension and exposure
to potentially nephrotoxic antiretroviral medications were common in R3 participants, other traditional risk factors for
albuminuria and kidney disease, including diabetes, APOL1 high-risk genotype, and smoking were rare. Co-infection
with endemic pathogens may also be significant contributors to albuminuria, but co-infections were not evaluated in
the R3 study population.
Methods: In Aim 1, we will cross-sectionally compare the prevalence of albuminuria and established kidney disease
risk factors in a cohort of PWH to age- and sex-matched HIV-negative adults presenting for routine care at the Aminu
Kano Teaching Hospital in Kano, Nigeria. We will leverage stored specimens from 2500 R3 participants and enroll an
additional 500 PLWH recently initiated on ART (≤ 24 months) and 750 age- and sex-matched HIV-negative adults to
determine the contribution of HIV, hypertension, and other comorbid medical conditions to prevalent albuminuria.
In Aim 2, we will follow a cohort of 1000 HIV-positive, ART-treated and 500 HIV-negative normoalbuminuric adults for
30 months to evaluate the incidence and predictors of albuminuria.
Discussion: The findings from this study will support the development of interventions to prevent or address microalbuminuria in PWH to reduce kidney and cardiovascular morbidity and mortality. Such interventions might include
more intensive monitoring and treatment of traditional risk factors, the provision of renin-angiotensin aldosterone
system or sodium-glucose cotransporter-2 inhibitors, consideration of changes in ART regimen, and screening and
treatment for relevant co-infections.
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Background
In some forms of kidney disease, such as diabetic
nephropathy, the earliest detectable abnormality is often
microalbuminuria. Albuminuria is an independent risk
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factor for cardiovascular complications and is a predictor of end organ damage including chronic kidney disease (CKD) [1–4]. Even very low levels of albuminuria,
assessed as urine albumin/creatinine ratio (uACR), of
10–30 mg/g) have been associated with adverse cardiovascular and kidney events. [5, 6] Microalbuminuria is
used in the early detection of disease states characterized by microvascular dysfunction, such as preeclampsia
and diabetic nephropathy, as well as medication-induced
nephrotoxicity [7, 8]. Micro- and macroalbuminuria are
also important risk predictors for mortality in antiretroviral therapy (ART)-treated PWH, likely as a marker for
inflammation and endothelial activation [9, 10]. Albuminuria has been associated with decreased CD4 cell
counts and higher plasma viral loads in PWH, as well as
increased systemic T-cell activation and more rapid progression to AIDS [5, 11, 12].
In recently published data from our NIDDK-funded
R3 study [13, 14] among PWH, ages 18–69 years who
were on ART for ≥ 6 months, ~ 40% of 2500 enrolled
participants had some level of persistent albuminuria.
Why is albuminuria so common in this HIV-positive,
ART-experienced population? We hypothesized that
genetics play an important role, given the high prevalence of APOL1 renal risk variants in West Africa [13,
14]. However, genotyping in the R3 study revealed lower
than anticipated prevalence of the high-risk (HR) APOL1
genotype (6.2%), which has been associated with kidney
disease risk [13]. The high rates of albuminuria observed
in the R3 study population likely reflect a mix of both
reversible microvascular endothelial injury (inflammation driven) and non-reversible podocyte damage (irreversible and progressive to CKD). The current study is
designed to evaluate additional potential contributors to
the high observed rates of albuminuria observed in PWH
in Nigeria. APOL1 high risk genotype and traditional
risk factors (e.g., hypertension, diabetes, smoking) do
not fully explain the high rates of albuminuria in the R3
study population, although hypertension is likely to be a
significant contributing factor. In a prior study in Nigeria, adults with high normal blood pressure (BP) (systolic
blood pressure [SBP] 130–139 mmHg and/or diastolic
blood pressure [DBP] 85–89 mmHg) had higher rates of
microalbuminuria (12.9% vs. 4.1%) and cardiovascular
disease risk factors than those with optimal BP. Sickle cell
disease and sickle cell trait are also common, with sickle
cell trait affecting 1 in 12 African Americans and nearly
300 million people worldwide [15–17]. Although sickle
cell trait is often considered a benign condition, kidney
manifestations may include impaired urinary concentrating ability, hematuria, and papillary necrosis [17–21].
Although the relationship of sickle cell trait to long-term
CKD has not been firmly established, prior studies have
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showed a higher-than-expected prevalence of sickle cell
trait among participants with end stage kidney disease
(ESKD). [15, 22, 23]
Other factors that may contribute to albuminuria can
be broken down into three main categories: i) direct kid‑
ney injury (i.e., exposure to the ARV medication TDF,
which can cause tubulopathy); ii) immune activation/
inflammation from HIV or specific viral pathogens (e.g.,
Cytomegalovirus [CMV], hepatitis B or C) and/or other
endemic co-infections (e.g., parasitic infestations, tuberculosis); and iii) environmental factors/exposures (i.e.,
traditional medications, heavy metals, etc.). This study
will include an in-depth evaluation of direct kidney
injury and immune activation/inflammation. Depending
on results, future studies may evaluate potential environmental exposures.
Because R3 participants were ART-experienced, with
the majority receiving TDF at some point in their course,
another important research question is to determine
whether albuminuria is tubular or glomerular in etiology.
Tenofovir is an effective ARV medication, widely used in
first-line ART regimens [24, 25]. Although data suggest
that it is not universally associated with kidney toxicity
[26–30], it can be associated with renal tubular dysfunction, including Fanconi syndrome [25, 30–33]. This is
especially important in our study setting, where the alternative formulation of tenofovir, tenofovir alafenamide
(TAF), which has a more favorable bone and kidney toxicity profile, is not routinely available.
Despite improved patient survival with ART [34, 35],
non-AIDS defining conditions such as cardiovascular
and kidney disease and non-AIDS-defining malignancies are more prevalent among ART-treated HIV-positive
than HIV-negative adults [34, 36–39]. While factors such
as smoking and ARV-related toxicity explain some of the
increased risk for these events [34, 40], excess immune
activation, inflammation, and poor immune restoration
[34, 41–51] have also been shown to predict disease.
Chronic immune activation and inflammation are hallmarks of HIV infection. [34, 51, 52]
A diverse array of plasma biomarkers [53], including
indices of T-cell activation [34, 54, 55], soluble tumor
necrosis factor receptor I (sTNFR-I), sTNFR-II, and
interleukin-6 (IL-6) [52, 56] are elevated in untreated
HIV infection and often remain elevated among ARTtreated adults who are fully virologically suppressed [34,
37, 47, 57, 58]. Many mechanisms have been proposed
to explain this inflammatory state, including the direct
effects of HIV replication (specifically viral protein production), HIV-mediated destruction of mucosal barriers
with chronic exposure to gut microbial elements, and
coinfections (e.g., CMV) [34, 59, 60]. Recent studies have
shown that morbidity and/or mortality are associated
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with serum inflammation biomarkers, including IL-6,
fibrinogen, C-reactive protein, soluble CD14 (sCD14),
D-dimer, and cystatin C [34, 41, 42, 45, 46, 48, 49, 61].
Tenorio et al. showed that higher levels of IL-6, sTNFR-I,
sTNFR-II, D-dimer, and sCD14 at baseline and pre-event
time points were associated with non-AIDS-related morbidity or death [34]. These effects were independent of
traditional risk factors, other comorbid conditions, age,
ART regimen, and ART-associated immunologic recovery [34].
Systemic inflammation in persons with HIV may also
occur in the setting of co-infections. For example, inflammation from parasitic infections, including malaria may
cause clinical manifestations [62–69]. Parasitic infections
can present with a range of glomerular diseases, most
commonly membranoproliferative glomerulonephritis,
while membranous glomerulopathy, focal segmental glomerulosclerosis (FSGS), and minimal-change disease are
also occasionally seen [67, 68]. In West Africa, chronic
parasitic infestations such as schistosomiasis (Schisto‑
soma haematobium and mansoni), filariasis (Wuchereria
bancrofti), onchocerciasis (Onchocerca volvulus), strongyloidiasis (Strongyloides stercoralis), and Loiasis (Loa
loa) are potential infectious causes of nephrotic and
nephritic syndromes [67, 68, 70]. In addition to overt kidney injury, parasitic infections may also promote local or
systemic inflammation, as indicated by elevated levels of
inflammatory biomarkers [69, 70].
Co-infection with certain viruses, such as CMV and
hepatitis B and C, are common among PWH [71].
Among PWH, CMV seropositivity has been associated
with persistent CD8 T-cell elevation and increased risk
of developing non-AIDS comorbidities, despite longterm ART [72, 73]. CMV-seropositive individuals with
and without HIV have increased epithelial gut damage,
microbial translocation, and inflammation. However, little is known about the prevalence and impact of CMV
in Nigeria. The estimated prevalence of hepatitis B virus
(HBV) and hepatitis C virus (HCV) is 7.6% and 1.7%,
respectively, among Nigerian adults (15–64 years of age)
[74]. Various forms of kidney injury have been described
in relation to HBV, including membranous nephropathy,
membranoproliferative glomerulonephritis, and polyarteritis nodosa [69, 75]. In addition to these viral coinfections, mycobacterial infections may present with a
diverse spectrum of kidney injuries, including post-infectious glomerulonephritis. Co-infection with M. tubercu‑
losis (TB), which is endemic in West Africa, particularly
among HIV-positive individuals, is also associated with
multiple nephropathies including chronic interstitial
nephritis and proliferative glomerulonephritis [76].
To better understand the high rates of microalbuminuria in our population, we plan to test the following
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overarching hypothesis: hypertension (including prehypertension), immune activation from co-infections,
and cumulative, long-term exposure to potentially
nephrotoxic ARV medications contribute to the high
rates of persistent microalbuminuria in these ART-experienced adults. To evaluate this overarching hypothesis,
we plan the following specific aims, with each aim having
its own additional supporting hypothesis or hypotheses:
1) To compare the prevalence of albuminuria and established kidney disease risk factors in a large cohort of
PWH to age- and sex-matched HIV-negative adults
presenting for routine medical care at the Aminu
Kano Teaching Hospital (AKTH) in Kano, Nigeria.
Hypothesis: HIV-negative adults will have lower prevalence of albuminuria, as well as lower prevalence of
hypertension and hepatitis B and C co-infection, when
compared to PWH.
2) To determine the role that hypertension and other
comorbid medical conditions (e.g., sickle cell trait or
disease, immune activation/inflammation from parasitic, viral, and bacterial infections, and exposure to
potentially nephrotoxic ARV medications), have on
the risk for development of albuminuria. Hypothe‑
ses: a) Participants with hypertension (controlling for
age and stage of hypertension) will have significantly
higher rates of albuminuria; b) ongoing inflammation,
as evidenced by higher levels of traditional and kidney-specific inflammatory biomarkers, will be associated with higher rates of albuminuria; and c) cumulative exposure to TDF significantly contributes to risk
of incident albuminuria among PWH.

Methods/design
Aim

The goal of this study is to better understand the factors contributing to the high rates of microalbuminuria
observed in virologically suppressed PWH in Nigeria.
By establishing an age- and sex-matched HIV-negative
cohort and screening both study populations for cofactors including viral (CMV, hepatitis B & C), parasitic,
and mycobacterial (TB) coinfections that may lead to
immune activation/inflammation, as well as long-term
exposure to potentially nephrotoxic ARV medications
(particularly TDF) among PWH, we anticipate our study
findings to inform the development of specific interventions to address albuminuria and result in reductions of
kidney and cardiovascular morbidity and mortality.
Setting

This study will be conducted in the U.S. President’s
Emergency Plan for AIDS Relief (PEPFAR)-funded HIV
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clinic at AKTH in Kano, a state in northwest Nigeria.
Kano is the most populous state in Nigeria and has an
HIV prevalence of 1.3% [77]. AKTH is a large tertiary
center that provides care for more than 10,000 adult
PWH. Potentially eligible study participants for this
study will be identified from 2 main clinics located on
the grounds of AKTH; (i) the HIV-negative adults will
be identified from the General Outpatient Department
(OPD) and the (ii) newly enrolled PWH plus the R3 participants called back (Fig. 1) will be identified from the
Prof. S.S. Wali Virology Centre. AKTH has longstanding collaborations with Vanderbilt University Medical
Center and is the site for multiple clinical trials, primarily funded by the U.S. National Institutes of Health
(NIH) and the Bill and Melinda Gates Foundation.
Study design

The study includes 2 specific aims; a cross-sectional
Aim (Aim 1) and a longitudinal Aim (Aim 2) (see below
and Fig. 1).

Fig. 1 Enrollment Chart

Page 4 of 17

Specific aim 1
Study population

The inclusion criteria are as follows:
• 18–69 years of age
• Willing and able to provide informed consent.
The exclusion criteria are:
• Pregnant (all women with reproductive potential will
undergo urine pregnancy testing)
• Known congenital kidney disease or autoimmune
disease (e.g., systemic lupus erythematosus) that can
cause albuminuria
Study procedures

HIV‑negative adults Trained study staff will present the
recruitment script at the time of screening. After subjects
provide informed consent, HIV-negative participants will
be tested for HIV in accordance with existing national
standard/policy as follows:

Wester et al. BMC Infectious Diseases

(2022) 22:591

• Participant will undergo point-of-care (POC) HIV
rapid testing (via finger prick)
• If their POC HIV rapid test is positive, the Determine HIV-1/2 assay kit (Abbott Laboratories) with
UniGold test (Trinity Biotech) will be used as the
confirmatory test. If needed, the HIV-1/2 STAT-PAK
Dipstick assay (Chembio Diagnostic Systems will be
used as tiebreaker.
• If their confirmatory HIV testing is positive, they
are not eligible to continue in the study but will be
informed of their status and will receive appropriate counseling by study staff, all of whom have IRB
training and extensive HIV counseling experience.
They will be referred for care per existing national
standards. If the HIV test is negative, participants
will be asked to complete a brief risk assessment, asking, “Have you engaged in any high risk (i.e., unprotected intercourse with a person with known HIV or
unknown HIV status, etc.) one or more times within
the prior 4–6 weeks?” (NOTE: those who are currently healthcare workers will also be asked if they
have had any needlestick and/or mucous membrane
exposures from someone with known HIV-positive
or unknown HIV status within the prior 4–6 weeks).
Based on responses to the risk assessment question,
subjects deemed high-risk (answering yes to any
question), will undergo viral load (VL) testing.
• ALL consenting subjects with a negative POC HIV
rapid test at their screening visit, regardless of their
responses to the above risk assessment question, will
be asked to provide urine specimens at the study
clinic (visits 1 and 2) for uACR measurement. They
will also have a blood specimen obtained for genetic
testing (at visit 2; see Table 1).
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• When VL results are available (in ~ 2–3 weeks), participants will be called back to receive results and
counseling to reduce transmission risk or for referral
to care if HIV-positive. Screened high-risk individuals having a detectable VL (> 50 copies/mL) are not
eligible for the study and will be provided counseling
and referral to care, as detailed above.
Visit specifics are outlined in Table 1 (see above) for
the newly enrolled 1250 study participants (500 HIVpositive adults on ART < 24 months plus the age- and
sex-matched 750 HIV-negative adults) and in Table 2
(see below) for the 2,000 R3 participants that will be
called back. Cross-sectional study visits will be completed by 1250 total participants, including 500 HIVpositive, ART-treated adults (18–69 years of age) on ART
for < 24 months, plus 750 age- and sex-matched HIVnegative adults (Fig. 1). We will measure urinary albumin
and creatinine levels to calculate a mean (two-sample)
uACR. In the 500 HIV-positive adults, we will also measure urine protein (once at Visit 1) to perform a urine
albumin-to-protein ratio (uAPR). In addition, we will
call back R3 participants who completed screening but
were not enrolled in the randomized trial for additional
measurements. We anticipate obtaining these additional
measurements from ~ 2000 R3 participants (conservatively assuming 90% re-consent). In participants called
back from R3, we will obtain one uACR measurement
(to confirm their current albuminuria status), one uAPR
measurement (to evaluate the potential impact of current/prior TDF exposure), and serum creatinine. We will
leverage archived specimens for HBV and CMV serology
testing. HCV antibody testing will be performed if we
identify a higher-than-expected prevalence in a random
sample of 200 PWH.

Table 1 Procedures for cross-sectional cohort of age- and sex-matched HIV-negative participants (n = 750), plus the newly enrolled
HIV-positive, ART-treated adults (on ART for < 24 months) (n = 500)
Visit 1

Visit 2 (4–8 weeks after Visit 1)

– Screening, informed consent
– HIV testing (HIV-negative participants only)
– Blood pressure measurement
– Diabetes screeninga
– Enrollment (if meet eligibility criteria)
– Participant to provide urine specimen at study clinic on day of visit (for 1st
uACR and for urine albumin-to-protein ratio (uAPR) (if HIV-positive))

– Participant to provide urine specimen at study clinic on day of visit (for
2nd uACR)
– Specimen collection (~ 6 tubes; ~ 30 mL total)
i) Genotyping (Two DBS cards)
ii) Serum creatinine (3 mL gold top tube)
iii) HBVb and HCV testingc (Two 3.5 mL gold top tubes)
iv) CMV testingd (One 3.5 mL gold top tube)
v) Additional specimens to store (Two urine aliquots: Two 3 mL EDTA tubes;
toenail/hair samples from consenting patients)

a

Screen for diabetes (if symptomatic, e.g., polyuria, polydipsia, weight loss), perform fasting/random glucose test (point-of-care device) and if ≥ 6.1 mmol/L (110 mg/
dL), then patient has possible diabetes, and is referred to medical provider/clinic for further evaluation

b

Screen initially with hepatitis B surface antigen, and if positive, perform hepatitis B e Ag and hepatitis B DNA (viral load)

c

Screen initially with hepatitis C antibody (due to anticipated low prevalence (< 1%), we will test a random sample of 200 HIV-positive adults and perform additional
screening (stored samples) only if prevalence > 2%)
d

Screen for Cytomegalovirus (CMV) using IgG antibody tests
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Table 2 Procedures for one time cross-sectional study visit for the HIV-positive, ART-treated adults that participated in the Renal Risk
Reduction (R3) study and now called back (n = 2,000)
Visit 1

-Screening, informed consent
-Blood pressure measurement
-Diabetes screeninga
-Enrollment (if meet eligibility criteria)
-Participant to provide urine specimen at study clinic on day of visit (for
uACR and uAPR)

a

-Participant to provide urine specimen at study clinic on day of visit (for
one-time uACR and uAPR)
Specimen collection (~ 3 tubes; ~ 15 mLs total)
i) Serum creatinine (3 mL gold top tube)
ii) HBVb and HCV testingc (leverage existing stored plasma aliquots)
iii) CMV testingd (leverage existing stored plasma aliquots)
iv) Additional specimens to store (Two urine aliquots: Two 3 mL EDTA tubes;
toenail/hair samples from consenting patients)

Screen for diabetes (if symptomatic, e.g., polyuria, polydipsia, weight loss), perform fasting/random glucose test (point-of-

care device) and if ≥ 6.1 mmol/L (110 mg/dL), then patient has possible diabetes, and is referred to medical
provider/clinic for further evaluation
b

Screen initially with hepatitis B surface antigen, and if positive, perform hepatitis B e Ag and hepatitis B DNA (viral load)

c

Screen initially with hepatitis C antibody (due to anticipated low prevalence (< 1%), we will test a random sample of 200

HIV-positive adults and perform additional screening (stored samples) only if prevalence > 2%)
d

Screen for Cytomegalovirus (CMV) using IgG antibody tests

Data collection and privacy considerations Following
enrollment, study participants will be assigned unique
study identification numbers for deidentified collection
of study data elements. Study visits with trained personnel will be held in private interview rooms located at
AKTH. We will use REDCap for standardized, HIPAAcompliant, secure data collection using case report
forms (CRFs).
Study measures

Urine albumin‑to‑creatinine ratio (uACR) In the Aim
1 cross-sectional arm, we will determine an average
uACR (based on 2 uACR measurement values obtained
4–8 weeks apart) for the 500 newly enrolled HIV-positive,
ART-treated adults (on ART < 24 months) plus the 750
age- and sex-matched HIV-negative controls. We will
obtain one confirmatory uACR from the 2000 HIV-positive, ART-treated adults that we will call back from the
R3 Study; all these participants have two uACR measurements from the R3 screening phase.
Urine albumin‑to‑protein ratio (uAPR) As a rough
estimate of glomerular vs. tubular injury). In the
Aim 1 cross-sectional arm, we will obtain one uAPR
from all HIV-positive ART-treated adults (including the 500 newly enrolled HIV-positive adults [on
ART < 24 months] plus the 2000 ART-experienced PWH
who we call back from the R3 Study.
Kidney function (Estimated glomerular filtration rate
(eGFR) measurement (serum) (i.e., creatinine); In the
Aim 1 cross-sectional arm, we will obtain one serum
creatinine (SCr) measurement from each participant.

Hepatitis B and C infection status Hepatitis B infection
status to be ascertained via serum hepatitis B surface antigen testing, with hepatitis C infection status to be ascertained via serum hepatitis C antibody testing.
Cytomegalovirus (CMV) Infection status. Ascertained
via serum CMV IgG antibody (Ab) testing.
Hypertension Study participant’s blood pressure will be
classified using current Joint National Commission (JNC)
8 guidelines; namely: Normal: Less than 120/80 mm Hg;
Elevated: Systolic between 120–129 and diastolic less
than 80; Stage 1: Systolic between 130–139 or diastolic
between 80–89; and Stage 2: Systolic at least 140 or diastolic at least 90 mm Hg.
Study outcomes

1. Prevalence
and
extent
of
albuminuria
(uACR > 30 mg/g), hypertension (e.g., elevated blood
pressure, Stage 1 hypertension, and Stage 2 hypertension), sickle cell trait and disease, hepatitis B & C
infection, and Cytomegalovirus (CMV) infection, all
stratified by HIV status.
2. Prevalence of APOL1 variants (high-risk (2 copies
of APOL1 risk variants) and low-risk (0–1 copies of
APOL1 risk variants), by HIV status.
3. Proportion of ART-treated adults with suspected
tubular albuminuria (urine albumin-to-protein ratio
(uAPR) < 40%) [24, 25] as identified during Aim 1
cross-sectional evaluation.
4. Proportion of ART-treated adults with suspected
glomerular albuminuria (albumin-to-protein ratio
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(uAPR) ≥ 40%) [24, 25] as identified during Aim 1
cross-sectional evaluation
Laboratory investigations
Albuminuria and proteinuria measurement

Urine biomarker assays (e.g., urine albumin, creatinine,
and protein measurements) will be performed at the
Bonventre laboratory (Brigham and Women’s Hospital Biomarker Laboratory, Boston, MA, USA) using the
Randox Imola platform (Crumlin, UK) for urine creatinine measurement and the Randox Imola or BNII nephelometer platforms (Siemens, Malvern, PA) for urine
albumin measurement (Bonventre laboratory). Specific
urinary measures will be performed using the kinetic
Jaffe method (creatinine), pyrogallol red colorimetry
method (protein) and immunoturbidimetry (albumin)
[78, 79]. Each participant will also provide a serum sample for creatinine, from which we will calculate eGFR
using the 2021 CKD-EPI equation, specifically, the 2021
eGFR creatinine (Age and Sex (AS)) equation) [80, 81].
For quality control and assurance (QC/QA) purposes,
we will utilize existing laboratory specimen handling
and analysis standard operating procedures that we have
developed and implemented in collaboration with the
Bonventre laboratory team.
Each screened participant will be given a unique study
ID number. The study subjects’ IDs can be linked back to
participants and will be maintained in REDCap on studyspecific secure (encrypted) tablets.
Genetics specimen collection and genotyping

Genotyping data are already available for participants
who completed the screening phase of the R3 study.
Dried blood spot (DBS) samples will be obtained for all
newly enrolled participants. DBS samples for genotyping
will be obtained by fingerprick, spotted (up to 125μL per
each 1 inch application) on Whatman FTA cards (Whatman, Brentford, UK) using capillary tubes and subsequently dried at room temperature for 1 h. We will store
the spotted Whatman FTA cards at room temperature
(20–25° C) with a desiccant for humidity-control, and
these cards will be shipped in batches to the Duke Molecular Physiology Institute (DMPI) Substrate Services Core
Facility. Once at DMPI, using sterile biopsy punches, the
team will take 6 mm punches from each dried-blood
spot sample, with the filter card punch to be placed
directly into an extraction tube, and the DNA isolated
using Qubit DNA extraction kits (Thermo Fisher Scientific, Waltham, MA). Two elutions will be performed
to increase the DNA yield, and DNA will be quantified
using PicoGreen dsDNA Assays (Thermo Fisher Scientific, Waltham, MA, USA). For genotyping and sample

Page 7 of 17

handling, we will check 2.5–5% of duplicate filter papers
for genotype match (and possibly run sex markers) for
sex match between clinical record and genotypic sex.
APOL1 genotyping will be performed in the Olabisi
laboratory at the DMPI using TaqMan assays (San Diego,
CA) targeting the 3 APOL1 variants (rs73885319 [G1],
rs60910145 [G1], and rs 71785313 [G2]) associated with
CKD and HIV-associated kidney disease. The APOL1
risk alleles are defined by G1 haplotypes (rs73885319-G/
rs60910145-G and rs73885319-G/rs60910145-T) and the
G2 haplotype (rs7175313-deletion). Testing for the chromosome 11 hemoglobin subunit beta (HBB) sickle cell
variants HbS (rs334; p. Glu6Val) and HbC (rs33930165,
p. Glu6Lys) will be performed using TaqMan assays.
Other genetic loci associated with kidney disease or with
susceptibility to infections may also be studied on an
exploratory basis. We will define the APOL1 genotype
from the number of risk alleles. In recessive models, individuals exhibiting two risk alleles (G1/G1, G1/G2, or G2/
G2) will be assigned to the high-risk (HR) group, while
individuals carrying no or one risk allele (G0/G0, G0/G1,
and G0/G2) will be assigned to the low-risk (LR) group.
We will also perform exploratory analyses to examine the
number of risk alleles (0, 1, or 2 alleles).
All information linking participants to personal identifiers will be destroyed once study follow-up and data
analysis are completed. Individual participant data to
be collected and maintained by de-identified study code
include age, ethnicity, sex, occupation, weight, BMI,
comorbid medical conditions (hypertension, diabetes,
opportunistic infections, syphilis, cancer, cardiovascular
disease, and other conditions of potential relevance to
study outcomes), current ART regimen (for HIV-positive
participants), and concomitant medications. Data on
prior and current use of TDF, indinavir, and ritonavirboosted protease inhibitors will be collected from HIVpositive participants and from review of the medical
chart.
Statistical considerations
Sample size

We enrolled 2500 PWH during the screening phase of
R3. For these calculations, we assume a similar prevalence of albuminuria among the 500 participants newly
recruited for this study. Of note, even if none of the
500 new recruits have albuminuria, the overall proportion among HIV-positive participants will be > 33%, and
power calculations (i.e., detectable relative risks) are similar. Table 3 shows, for given sample sizes, the proportion
of HIV-negative controls with uACR > 30 mg/g that we
would be able to detect with 90% and 80% power at the
alpha = 0.05 level (i.e., with a two-sided p-value < 0.05).
For example, with 750 HIV-negative controls, we will
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Table 3 Detectable proportion with microalbuminuria/macroalbuminuria with various sample sizes
Number of HIV-negative participants (N = 3000 HIV-positive
participants)

Detectable proportion with micro-/macroalbuminuria among HIVnegative controls (RR = relative risk)
90% power

300

80% power

0.306 (RR = 1.31)

500

0.319 (RR = 1.25)

0.325 (RR = 1.23)

750

0.335 (RR = 1.19)

0.336 (RR = 1.19)

1000

0.345 (RR = 1.16)

0.343 (RR = 1.17)

0.350 (RR = 1.14)

Bolded numbers on far left (750) for each of these tables reflect our chosen final sample size for number of HIV-negative participants to be enrolled

Table 4 Detectable mean difference for continuous outcome (in
SDs) between HIV + and HIV- participants
Number of HIV-negative participants
(n = 3000 HIV-positive participants)

Detectable difference
between mean uACR in
HIV-positive and HIVnegative participants
(standard deviations)

Table 5 Interaction effects based on hypertension
Number of
HIV-negative
participants

Albuminuria
prevalence for
HIV-negative
participants
without
hypertension

Albuminuria
prevalence for
HIV-negative
participants
with
hypertension

Relative Risk
(HIV-negative
participants)

90% power

80% power

750

0.10

0.27

2.7

300

0.196

0.170

750

0.15

0.36

2.4

500

0.157

0.135

750

0.20

0.44

2.2

750

0.132

0.114

750

0.25

0.50

2.0

1000

0.118

0.102

Bolded numbers on far left (750) for each of these tables reflect our chosen final
sample size for number of HIV-negative participants to be enrolled

have ~ 90% power to detect a relative risk for albuminuria
between HIV-positive and HIV-negative participants of
1.19 (0.400 vs. 0.336, respectively).
In preliminary data from the R3 cohort, only 4% of participants were LTFU between the two uACR measurements. To account for LTFU, we conservatively estimate
that we will need to recruit ~ 810 HIV-negative participants and ~ 540 newly enrolled HIV-positive participants
(~ 8% LTFU). We plan to do analyses both categorizing
uACR (> 30 mg/g) and treating it as a continuous variable. From our preliminary R3 study data, the mean uACR
among HIV-positive adults was ~ 67 mg/g (standard
deviation 266 mg/g). If our data are similarly skewed in
this study, we will transform the data before analyzing.
The mean log10 transformed uACR among HIV-positive
adults was 1.35 log10 (mg/g) with SD = 0.554 log10(mg/g).
Therefore, with n = 750 HIV-negative and 3000 HIVpositive participants, we anticipate having ~ 90% power
to detect a difference in mean log10-transformed uACR
between HIV-positive and HIV-negative adults of 0.132
standard deviations or 0.07 (i.e., 1.35 log10(mg/g) in HIVpositive vs. 1.28 log10(mg/g) in HIV-negative adults, corresponding to a median uACR of ~ 22.4 vs. 19.0 mg/g.

The calculations in Table 3 (and Tables 4 and 5) do not
account for loss-to-follow-up (LTFU) between the two
uACR measurements in the cross-sectional study. In our
preliminary data, only 4% of patients were LTFU between
the two measurements. Power is greater (although clinical interpretation may be more challenging) when uACR
is treated as a continuous outcome. We plan to do analyses both categorizing uACR (> 30 mg/g) and treating it as
a continuous variable. We therefore also present power
evaluating uACR as a continuous outcome (Table 4).
With 750 HIV-negative and 3000 HIV-positive participants, we will have ~ 90% power to detect a difference of
0.132 standard deviations between the mean outcome in
HIV-negative vs. HIV-positive adults. From our preliminary data, the mean uACR among HIV-positive adults
was ~ 67 mg/g (standard deviation 266 mg/g). This is
quite skewed, so we will transform the data before analyzing. The mean log10 transformed uACR among HIV-positive adults was 1.35 log10 (mg/g) with SD = 0.554 log10
(mg/g). Therefore, with n = 750 HIV-negative and 3000
HIV-positive participants, we anticipate having ~ 90%
power to detect a difference in mean log10-transformed
uACR between HIV-positive and HIV-negative adults
of 0.07 (i.e., 1.35 log10(mg/g) in HIV-positive vs. 1.28
log10(mg/g) in HIV-negative adults, corresponding to
median uACR of ~ 22.4 vs. 19.0 mg/g.
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Power calculations for interaction effects

We will examine whether the association between risk
factors and albuminuria differs between HIV-positive
and HIV-negative participants. Table 5 illustrates the
power for detecting interaction effects based on hypertension. From preliminary R3 data, 12.7% of our study
participants had Stage 1 or 2 hypertension (JNC-7 classification). Overall, 47% of HIV-positive adults with hypertension had albuminuria, and 39% of HIV-positive adults
without hypertension had albuminuria, for a relative risk
of 1.22. If the prevalence of hypertension is ~ 10% among
our HIV-negative participants, then Table 5 shows the
relative risks among HIV-negative individuals for which
we anticipate having ~ 80% power to detect based on
varying prevalence of albuminuria. For example, with 750
HIV-negative adults and a true prevalence of albuminuria of 0.25 among HIV-negative adults who do not have
hypertension, we have 80% power to detect a difference
of relative risks for hypertension of 1.22 vs. 2.0 between
HIV-positive and HIV-negative participants, respectively
(Bold emphasis row, Table 5).
Statistical analysis plan

We will fit regression models based on categorized (i.e.,
logistic regression) and continuous (i.e., linear regression after 
log10 transformation and/or semiparametric
cumulative probability models that empirically estimate
the transformation) uACR levels [82]. HIV status is the
primary exposure variable. We will perform additional
analyses to investigate the interaction between HIV status and individual risk factors, including hypertension
and co-infection (HBV and CMV), to determine whether
associations differ based on HIV status (e.g., whether the
impact of comorbidities on microalbuminuria is greater
among PWH). Regression models will be adjusted for
potential confounders, including age, ethnicity, smoking
status, and BMI. Primary analyses will control for sex and
will be repeated among men and women, separately, to
investigate potential differences by sex. For the analyses
limited to PWH, viral load (detectable/undetectable) will
be included in models as a potential confounder. Missing
data will be multiply imputed using standard techniques.
Continuous covariates will be expanded using restricted
cubic splines with three knots to avoid linearity assumptions. Additional analyses will be performed in the subset
of HIV-positive adults to assess the association between
HIV-specific factors (e.g., TDF exposure, duration on
ART, detectable viral load, and CD4 cell count) on albuminuria/uACR (Additional file 1 and Additional file 2).
Genetic analysis plans

We will determine the prevalence of APOL1 risk alleles,
comparing the 750 HIV-negative adults to our 3000
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HIV-positive study participants, specifically comparing the proportions of each population (i.e., HIV-negative vs. HIV-positive) possessing 0, 1, and 2 APOL1 risk
haplotypes (G1 or G2). We will examine the association
between APOL1 genotype and uACR and eGFR, adjusting for sex, age, and HIV status. Furthermore, we will test
whether the associations between APOL1 genotype and
our outcomes differ by HIV status by including interaction terms. Based on prior genetic association work in
HIV-associated kidney disorders [83–89], we will test
both additive and recessive genetic models.
Specific aim 2
Study population

The inclusion criteria are as follows:
• Participants
with
normoalbuminuria
(uACR < 30 mg/g) who complete Aim 1 are eligible
for Aim 2 (Fig. 1).
• Participants that completed Aim 1 of the separate,
ongoing R3 study [13, 14] having normoalbuminuria
(uACR < 30 mg/g) based on the average of two previously obtained uACR measurements (4–8 weeks
apart) and re-confirmed via an additional uACR
measurement obtained at time of screening for this
study are also eligible.
Exclusion criteria

• Did not complete all scheduled Aim 1 visits
• Pregnancy (all women with reproductive potential
will undergo urine pregnancy testing)
• Diabetes mellitus (documented diagnosis or random
glucose ≥ 6.1 mmol/L [110 mg/dL])
• Known congenital kidney disease and/or autoimmune disease that can cause albuminuria
• Actively taking ACEi or ARBs, which may suppress
albuminuria
• Regular use of NSAIDs or traditional medications
• HIV-negative but use TDF as pre-exposure prophylaxis or HBV treatment
• Comorbid condition with life expectancy < 3 years
• Planning to relocate within three years
Study procedures

Whole blood and urine biospecimens will be obtained
for processing for plasma and urine pellets which will
be processed and shipped to their respective research
laboratories, namely, Duke University (plasma biomarker,
Cytomegalovirus (CMV) IgG antibody (Ab) testing, and
APOL1 genotyping) and Brigham and Women’s Hospital
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(urine biomarkers and urine albumin, creatinine, and
protein testing). Participants will receive reimbursement
for comprehensive study visits. All HIV-negative study
participants will be asked to complete a brief risk assessment at each study visit, with reflex viral load testing in
those deemed high risk, as outlined in Aim 1 (study procedures). If their HIV test results are positive, they will
no longer participate in longitudinal follow-up. Data collected prior to seroconversion will be maintained. Longitudinal assessments (enrollment visit and then every
6 months for 30 months for a total of 5 scheduled visits
for each participant) will include the following (as out‑
lined below):
Study measures

Demographic and clinical data elements will be
abstracted from medical record and by self-report at
baseline and will be updated during every scheduled
study visit.
• Demographics: age, sex, self-reported ethnicity
(Hausa/Fulani, Igbo, Yoruba, Other (Specify)
• Education: not literate, primary, secondary, tertiary
(university or other college).
• Occupation: employment status (and if employed;
details to be obtained)
• HIV transmission risk factors: heterosexual activity,
homosexual activity, transfusion, other, unknown
• Date of HIV diagnosis (PWH only): date of first positive HIV test
• Date of ART initiation (PWH only): defined as three
or more active antiretrovirals from two or more drug
classes
• Dates of AIDS-defining illnesses (PWH only): defined
per CDC list of AIDS-defining illnesses
• Dates of comorbid disease diagnoses: infections
including TB (pulmonary and extrapulmonary), viral
infections (HBV, HCV [Aim 1], Lassa fever, COVID19, etc.), AIDS-defining illnesses; NCDs including
hypertension, diabetes, sickle cell trait or disease,
dyslipidemia, cardiovascular disease, cancer, liver
disease, lung disease, depression, and bone mineral
density abnormalities (including non-traumatic fractures).
• Antiretroviral medication start/stop dates (PWH
only): from clinical record and pharmacy data (evaluating current exposure as well as prior/current TDF,
protease inhibitor use to determine cumulative exposure time).
• Current medications: all medications taken at least
once daily for ≥ 30 days, including traditional medications.
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• Laboratory HIV data: all CD4 cell count and viral
load measurements (collected per standard of care).
SARS-CoV-2 testing will be performed per existing
standard of care and results of all COVID-19 screening tests will be captured in the patients’ study medical record).
Social and behavioral data will be collected three times
during study follow-up using the following scales, which
are all available in both English and Hausa languages
(Table 6).
• Substance use: The Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST) is a cross-cultural screening of recent and lifetime substance use
[90].
• Depression: The 9-item Patient Health Questionnaire
(PHQ-9) [91] screens for depressive symptoms.
Clinical Assessments at all comprehensive study visits will be performed by trained study nurses and will
include:
• Vital signs: temperature, respiratory rate, heart rate,
blood pressure (Seated BP checked every study visit
using a validated Omron series 5 upper arm digital
BP device).
• Anthropometrics: height, weight, waist circumference
• Urine albumin testing, uACR measurements: Albuminuria will be assessed at each visit and categorized as
defined in Aim 1. Subjects with incident macroalbuminuria will be referred to a clinician for evaluation
and to a nephrologist for additional testing/management, per standard of care.
• Urine albumin-to-protein [uAPR] ratios (HIV-positive
participants): will be assessed to screen for possible
TDF-mediated tubular insult as a contributing cause
of microalbuminuria. Subjects with uAPR < 40% will
be classified as tubular albuminuria and those
with uAPR ≥ 40% will be classified as glomerular
albuminuria.
• Diabetes screening: All potentially eligible Aim 2 participants will undergo fasting/random blood glucose
testing to evaluate for diabetes (and if ≥ 6.1 mmol/L
(110 mg/dL), then patient may have diabetes, is ineligible, and is referred to medical provider/clinic for
evaluation. Once enrolled, during each study visit,
participants will be screened for symptoms of diabetes. In those with symptoms, we will perform fasting/random blood glucose testing. if ≥ 6.1 mmol/L
(110 mg/dL), they will be immediately referred to a
specialist for further evaluation.

Wester et al. BMC Infectious Diseases

(2022) 22:591

Page 11 of 17

Table 6 Procedures for longitudinal cohort of HIV-positive (n = 1,000) and HIV-negative (n = 500) participants with normoalbuminuria
to be followed for 30 months (n = 1500 total)
Procedure / Visit (month (mo))

Enrollment

6 mo 12 mo 24 mo 30 mo

Seated blood pressure check

X

X

X

X

X

Diabetes mellitus screening (perform fasting blood glucose if any signs/symptoms suggestive of X*
underlying diabetes)

X

X

X

X

uACRa (No urine protein testing necessary for enrolled Aim 2 HIV-positive adults with normoalbuminuria as all HIV-positive ART-treated adults from Aim 1 will have one uAPR measurement)
(We will have stored urine at 3 timepoints to go back and perform uAPR testing in patients with
incident microalbuminuria)

X# (We will use
Aim 1 uACR as participants baseline
value)

X

X

Serum creatinine (SCr)b

X (We will use
Aim 1 SCr as their
baseline value)

X

X

Parasite screening
Complete blood count (CBC) with differentialc

X

X

X

X

X

Urine dipstick (spun for all patients with hematuria followed by urine microscopy (S. haematobium)

X

X

X

X

X

X

X

X

X

Malaria testing (rapid diagnostic test) at point-of-care (POC) using fingerprick specimen

X

Filariasis POC testing for Wuchereria bancroftid

X

Onchocerciasis testing (bilateral skin snips)e

X

Stool for ova and parasite (stool O&P)f

X

Daytime thick blood smear for Loa loa (10 AM–2 PM)

X

Strongyloides IgG serology (plasma)g

X

Tuberculosis screeningh

X

Inflammatory biomarkers (urine and plasma)i

X

X

CD4 cell count

X

X

X
X
X

X

X

X
X
X

X

X

X

X

Viral load (plasma HIV RNA)

X

Social and Behavioral data

X

X

X

X

Additional tubes for storagej

X

X

X

*All potentially eligible Aim 2 participants will undergo fasting blood glucose testing to evaluate for diabetes (and if ≥ 6.1

mmol/L (110 mg/dL), then patient may have diabetes, is ineligible, and is referred to medical provider/clinic for evaluation
#

All participants will use their recent uACR measurement (obtained in Aim 1) for their baseline

a

Two 3 mL sterile universal containers taken for uACR testing (Urine protein testing only for HIV-positives)

b

Two 3 mL gold top tubes taken to measure serum creatinine (SCr)

c

CBC with differential—looking for eosinophilia (common with Filariasis (especially Loa loa) and Schistosomiasis)

d

POC testing for W. bancrofti antigen by Filariasis Test Strip (FTS), followed by obtaining nocturnal thick blood smears for

microfilaria [between 10 pm—2 am] in FTS-positive persons. Brugia spp. are not endemic to Africa, so testing for W
bancrofti will be sufficient
e

Onchocerca volvulus ELISA is not sensitive enough to rule out infection. Physical exam findings are also not sensitive. No one

will want to be snipped every 6 months, but since filarial worms are long-lived (> 5 years), snipping at the beginning and end
of study should capture anyone who is infected at study onset or becomes infected during the study
f

Stool for O&P to be done screening for S. mansoni and soil transmitted helminths (e.g., Ascaris, Trichuris, Hookworm)

g

Strongyloides IgG ELISA at baseline in ALL participants & test all persons testing NEG at enrolment again at 30 months

h

Sputum specimens (5 mL) to be collected and sent for Gene Xpert testing and/or microscopy (acid fast bacilli staining)

i

Two 3 mL purple top tubes for plasma biomarkers and one 5–7 mL urine specimens for urine biomarkers (and stored)

j

Two 3 mL purple top EDTA tubes and one 5–7 mL urine specimen to be obtained and stored for future/approved testing

Co‑infection screening

• Mycobacterium tuberculosis (TB): Sputum specimens
for acid fast bacilli (AFB) microscopy and/or Gene
Xpert testing in patients having a cough of ≥ 2 weeks
in duration, weight loss, and/or night sweats). Mycobacterial blood cultures, lymph node aspirates, body

fluid (i.e., thoracentesis) and imaging studies will be
obtained per standard of care when evaluating for
suspected extrapulmonary TB.
• Parasitic infections (see Table 6) (The results
obtained from enrollment filariasis (W. bancrofti, O.
volvulus, and L. loa) screening will determine the
need for repeat testing at the 30-month visit (i.e.,
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if prevalence is extremely low, we will not re-test at
the 30-month visit).
Adverse clinical outcomes will be assessed at all study visits
by trained study research staff

• Hospitalizations: We will ask all participants if they
have been hospitalized in the previous 6 months. If
they answer affirmatively, we will ask the reason for
hospitalization and approximate dates.
• Death: Ascertained from medical records or from
a contact identified by the participant during consent.
• Inflammation will be assessed from plasma and urine
specimens collected, as detailed in Table 6. Plasma
inflammatory biomarker assay testing will be performed in duplicate at the DMPI Biomarker Core
Facility using the Mesoscale Discovery Platform.
Based on the literature, we chose a panel of plasma
and urine biomarkers [92–101] that will help us elucidate the processed by which chronic inflammation
contributes to albuminuria. Urine inflammatory/
tubular injury biomarker assay testing will be performed at the Bonventre laboratory (Brigham and
Women’s Hospital Biomarker Laboratory, Boston,
MA, USA). Some are novel biomarkers whose role in
clinical research is being defined.
• Plasma inflammatory markers: highly sensitive
C-reactive protein (hsCRP), IL-6, soluble TNF-receptor 1 (TNFR-1), soluble TNF-receptor 2 (TNFR-2),
IL-1β, and TNF (with biomarker levels of sCD14,
fibrinogen, and possibly additional plasma biomarker
levels to be ascertained pending additional funding/
approved sub-studies).
• Urine inflammatory/tubular injury biomarkers:
NGAL, KIM-1, and MCP-1 (with biomarker levels
of IL-18, interferon-gamma inducible protein-10 (IP10), and possibly additional urine biomarker levels to
be ascertained pending additional funding/approved
sub-studies).
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2.
3.
4.
5.

inflammation (high levels of plasma and/or urine
inflammatory marker levels) status.
Proportion experiencing a doubling of serum creatinine.
Proportion experiencing a decline in eGFR > 30% at
30 months (using the 2021 CKD-EPI eGFR creatinine
(age and sex)) equation.
Mean change in eGFR at 30 months (using the 2021
CKD-EPI eGFR creatinine (age and sex)) equation.
Mean change in uACR at 30 months.

Statistical considerations
Sample size

We will enroll 1500 (1000 HIV-positive and 500 HIVnegative) patients with normoalbuminuria and follow
them for up to 30 months. Table 7 summarizes differences in albuminuria incidence that we will have 80%
power to detect between the HIV-positive and HIVnegative groups, over a range of sample sizes and albuminuria incidence rates in the HIV-positive group. We
will have approximately 80% power to detect a difference of developing albuminuria of 10% (HIV-positive) vs.
5.9% (HIV-negative), or a relative risk of about 1.70 (Bold
emphasis row in Table 7).
Statistical analysis plan

Demographic and clinical characteristics will be summarized by descriptive statistics. We will perform two sets
of analyses: (1) categorizing uACR and investigating time
from enrollment to albuminuria onset (first uACR measurement > 30 mg/g), and (2) keeping uACR as a continuous variable and investigating mean change in repeated
uACR measures. Categorization of uACR is common
in the literature and allows easy clinical interpretation,
whereas continuous analysis tends to result in greater
power. For (1), discrete-time proportional hazards models with a complementary log–log link will be fit. For (2),

Table 7 Detectable alternative for various rates of developing
albuminuria for the HIV-positive adult patients
HIVpositive
adults, N

HIVnegative
adults, N

Study outcomes

1. Proportion of Aim 2 longitudinal cohort participants experiencing progression from normoalbuminuria (uACR < 30 mg/g) to microalbuminuria
(uACR = 30–300 mg/g), at 30 months of follow-up,
overall, and by TB infection, parasitic infection, and

3-year
incidence of
albuminuria
for HIVpositive
adults

3-year
Relative Risk
incidence of
albuminuria,
HIVnegative
adults, 80%
power to
detect

1000

500

5%

2.2%

2.28

1000

500

10%

5.9%

1.70

1000

500

15%

10.0%

1.51
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generalized estimating equations (GEE) with an identity
link (i.e., linear model) will be fit to repeated measures
of log10-transformed uACR. We will fit models limited
to PWH, with cumulative TDF exposure as the primary
(time-varying) exposure. The association between albuminuria and cumulative exposure to other regimens (e.g.,
protease inhibitors) will also be considered, both in models with and without cumulative TDF exposure. Analyses
will adjust for viral suppression status. Secondary analyses will exclude the anticipated small proportion (< 5%)
that will not be virally suppressed.
For hypothesis (ii), we will fit models with HIV status,
hypertension, and an interaction between HIV status and
hypertension. For hypothesis (iii), we will fit models with
time-updated biomarkers of inflammation, both current
and cumulative exposure. For inflammatory analyses,
we will compute a composite inflammation score [102]
for each participant that has been shown to accurately
predict the phenotype of interest, based on levels (at
least initially) of select markers, with a score of 1 being
assigned to each individual biomarker measurement
deemed “high” (or “significantly elevated”) delineated as
follows: hsCRP > 3 mg/L, IL-6 > 6 pg/mL, TNF ≥ 7 pg/mL,
and IL-1β ≥ 0.39 pg/mL. We will also perform analyses
including inflammation biomarkers as continuous variables, both individually and in combination with other
biomarkers.
Urine and plasma biomarkers will be collected and
stored on all Aim 2 study participants, but we will perform case–control analyses using cases defined as
participants who develop incident albuminuria during follow-up (i.e., incident cases) and compare their
biomarker profiles to a matched set of non-albuminuric controls. We conservatively estimate that we will
observe ~ 130 incident cases; we plan to match three
controls to each case based on age (± 10 years), sex, HIVstatus, CD4 cell count at enrollment among those HIVpositive (within 50 cells/mm3), and hypertension status.
If matching on this many factors proves to be difficult,
then we will consider matching on the predicted probability of being a case based on the factors listed above
(i.e., propensity score-type matching). We will account
for the case-cohort nature of the design with appropriate
analyses that account for outcome-dependent sampling
[103].
All analyses will account for confounding variables,
including time-updated viral suppression status (only
participants with suppressed viral load will be enrolled),
smoking status, BMI, CD4 cell count, age, exposure to
TDF or protease inhibitors, etc. We anticipate using propensity score matching weights [104], to account for the
high number of confounders, particularly in our time-toalbuminuria analyses (which will likely not have enough
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events to allow inclusion of all potential confounders).
In all analyses, to relax linearity assumptions, continuous predictors will be expanded using restricted cubic
splines.
Missing data, which we assume will be minimal, will be
imputed using multiple imputation procedures. The longitudinal nature of our data collection may also permit
investigation of mediation (e.g., hypertension → inflammation → albuminuria), which will be explored using
relevant methods [105].

Discussion
APOL1 high risk genotype and traditional risk factors
for kidney disease (e.g., hypertension, diabetes, smoking) do not fully explain the high rates of albuminuria
seen in our HIV-positive, ART-experienced adult Nigerian population, although hypertension is likely to be an
important contributing factor. Other factors that may
contribute to albuminuria can be broken down into three
main categories, two of which will be evaluated in-depth
in this study: i) direct kidney injury (i.e. exposure to the
ARV medication TDF, which can cause tubulopathy);
ii) immune activation/inflammation from HIV or specific viral pathogens (CMV, HBV, or HCV) and/or other
endemic co-infections (i.e. parasitic infestations, tuberculosis); and iii) environmental factors/exposures (i.e. traditional medications, heavy metals, etc.).
This study is innovative for the following reasons: (i)
The findings of this study, depending on which factors
are identified as contributing most to microalbuminuria,
will guide the design of interventions aimed at identifying and more aggressively managing microalbuminuria
in PWH earlier in their risk trajectory towards overt cardiovascular and kidney disease; (ii) This will be the first
study in sub-Saharan Africa to comprehensively evaluate
the interplay between genetic susceptibility (APOL1 risk
alleles), comorbid traditional risk factors, and chronic
inflammation/immune activation and endemic co-infections on microalbuminuria. Prior studies in this population have rarely considered the role of comorbid sickle
cell trait/sickle cell disease or the impact of co-infections
other than HBV or HCV.
The anticipated findings from this study will support
the development of interventions to address microalbuminuria in PWH to reduce kidney and cardiovascular
morbidity and mortality, including more intensive monitoring and treatment of traditional risk factors, provision
of renin-angiotensin aldosterone system or sodium-glucose cotransporter-2 inhibitors, consideration of changes
in ART regimen, and screening and treatment for relevant co-infections.
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Trial status
The current version of the protocol is version 6.0., with
enrollment slated to commence in July 2022. We anticipate enrollment for aim 1 to be completed by October
1, 2022, and enrollment for aim 2 to be completed by
December 31, 2022.
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